Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2015

Conditions
Essential ThrombocythemiaPolycythemia Vera
Interventions
DRUG

Imetelstat

Trial Locations (12)

21205

Johns Hopkins University - Bunting Blaustein Cancer Research Building, Baltimore

29601

Saint Francis Hospital, Greenville

32806

MDACC - Orlando, Orlando

60637

University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

80331

Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School, Munich

91010

City of Hope, Duarte

Unknown

University Hospital of Essen - West German Cancer Center, Essen

SLK-Kliniken GmbH, Heilbronn

University Hospital Regensburg - Uniklinik Regensburg, Regensburg

D-60590

Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität, Frankfurt

CH - 3010

INSELSPITAL, University Hospital Bern, Bern

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Geron Corporation

INDUSTRY